Please enable JavaScript to continue using this application.

Compare $LYEL vs $RNAC | Chartloom

Compare

$LYEL vs $RNAC

Lyell Immunopharma Inc · Cartesian Therapeutics Inc

LYEL

Lyell Immunopharma Inc

RNAC

Cartesian Therapeutics Inc

Compare $LYEL vs $RNAC

Comparing Lyell Immunopharma Inc and Cartesian Therapeutics Inc

LYELLyell Immunopharma Inc

RNACCartesian Therapeutics Inc

LYELLyell Immunopharma Inc

Market cap

$203M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

16,911.71x

Rev growth (TTM)

-55.0%

YTD performance

-69.9%

52W performance

-52.3%

FCF yield

-86.2%

RNACCartesian Therapeutics Inc

Market cap

$207M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

473.62x

Rev growth (TTM)

-20.7%

YTD performance

4.4%

52W performance

-31.0%

FCF yield

-37.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LYEL

RNAC

Detailed metrics comparison

LYEL

Lyell Immunopharma Inc

RNAC

Cartesian Therapeutics Inc

Market Cap

LYEL$203M

RNAC$207M

Enterprise Value

LYEL$130M

RNAC$113M

Price

LYEL$8.71

RNAC$7.06

P/E Ratio

LYELN/A

RNACN/A

P/S Ratio

LYEL7,526.09x

RNAC140.34x

EV/Sales

LYEL4,822.94x

RNAC76.18x

EV/EBITDA

LYEL0.00x

RNAC0.00x

P/B Ratio

LYEL0.97x

RNAC296.12x

P/FCF Ratio

LYELN/A

RNACN/A

EV/FCF

LYEL-0.74x

RNAC-1.43x

PEG Ratio

LYELN/A

RNACN/A

Forward P/E (NTM)

LYELN/A

RNACN/A

Forward P/S (NTM)

LYEL16,911.71x

RNAC473.62x

Revenue (TTM)

LYEL$27K

RNAC$1M

Revenue Growth (YoY)

LYEL-55.0%

RNAC-20.7%

Forward Rev Growth

LYEL7184.7%

RNAC-14.0%

Gross Margin (TTM)

LYEL0.0%

RNAC0.0%

Operating Margin (TTM)

LYEL0.0%

RNAC0.0%

EBITDA Margin (TTM)

LYEL-669059.3%

RNAC-6503.1%

Net Margin (TTM)

LYEL-920285.2%

RNAC-10422.5%

FCF Margin (TTM)

LYEL-648763.0%

RNAC-5322.4%

Net Income (TTM)

LYEL$-248M

RNAC$-154M

FCF (TTM)

LYEL$-175M

RNAC$-79M

EPS (TTM)

LYEL-$10.64

RNAC-$5.16

ROE (TTM)

LYEL-9162.0%

RNAC-321582.0%

ROA (TTM)

LYEL-7050.0%

RNAC-4761.0%

ROIC (TTM)

LYEL-9162.0%

RNAC-321582.0%

Cash

LYEL$73M

RNAC$148M

Debt

LYEL$0

RNAC$53M

Net Cash/Debt

LYEL$73M

RNAC$95M

Current Ratio (TTM)

LYEL5.36x

RNAC7.48x

Quick Ratio (TTM)

LYEL5.12x

RNAC7.19x

Debt/Equity (TTM)

LYEL0.00x

RNAC0.28x

Debt/Assets (TTM)

LYEL0.0%

RNAC0.0%

Interest Coverage (TTM)

LYELN/A

RNACN/A

Net Debt/EBITDA (TTM)

LYEL0.00x

RNAC0.00x

Beta

LYEL-0.04

RNAC0.74

52W Performance

LYEL-52.3%

RNAC-31.0%

YTD Performance

LYEL-69.9%

RNAC4.4%

% from 52W High

LYEL-80.6%

RNAC-35.9%

% from 52W Low

LYEL6.1%

RNAC26.0%

Asset Turnover (TTM)

LYEL0.00x

RNAC0.01x

FCF Yield (TTM)

LYEL-86.2%

RNAC-37.9%

Earnings Yield (TTM)

LYEL-122.3%

RNAC-74.3%

Dividend Yield (TTM)

LYELN/A

RNACN/A

Rule of 40

LYEL-648,818.0

RNAC-5,343.1

EV/GP/RG

LYELN/A

RNACN/A

Ticker research

View LYEL research View RNAC research

Metric	LYEL Lyell Immunopharma Inc	RNAC Cartesian Therapeutics Inc
Market & Valuation
Market Cap	$203M	$207M
Enterprise Value	$130M	$113M
Price	$8.71	$7.06
P/E Ratio	N/A	N/A
P/S Ratio	7,526.09x	140.34x
EV/Sales	4,822.94x	76.18x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	296.12x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.74x	-1.43x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	16,911.71x	473.62x
Revenue & Growth
Revenue (TTM)	$27K	$1M
Revenue Growth (YoY)	-55.0%	-20.7%
Forward Rev Growth	7184.7%	-14.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-669059.3%	-6503.1%
Net Margin (TTM)	-920285.2%	-10422.5%
FCF Margin (TTM)	-648763.0%	-5322.4%
Net Income (TTM)	$-248M	$-154M
FCF (TTM)	$-175M	$-79M
EPS (TTM)	-$10.64	-$5.16
ROE (TTM)	-9162.0%	-321582.0%
ROA (TTM)	-7050.0%	-4761.0%
ROIC (TTM)	-9162.0%	-321582.0%
Financial Health
Cash	$73M	$148M
Debt	$0	$53M
Net Cash/Debt	$73M	$95M
Current Ratio (TTM)	5.36x	7.48x
Quick Ratio (TTM)	5.12x	7.19x
Debt/Equity (TTM)	0.00x	0.28x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.04	0.74
52W Performance	-52.3%	-31.0%
YTD Performance	-69.9%	4.4%
% from 52W High	-80.6%	-35.9%
% from 52W Low	6.1%	26.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-86.2%	-37.9%
Earnings Yield (TTM)	-122.3%	-74.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-648,818.0	-5,343.1
EV/GP/RG	N/A	N/A
Ticker research	View LYEL research	View RNAC research

Valuation

P/S Ratio

RNAC

140.34x

LYEL

7,526.09x

EV/FCF

RNAC

-1.43x

LYEL

-0.74x

Growth & revenue

Revenue Growth TTM

RNAC

-20.7%

LYEL

-55.0%

Forward Revenue Growth

LYEL

7184.7%

RNAC

-14.0%

Profitability & performance

Gross Margin

LYEL

0.0%

RNAC

0.0%

ROE

LYEL

-9162.0%

RNAC

-321582.0%

FCF Yield %

RNAC

-37.9%

LYEL

-86.2%

52-Week Performance

RNAC

-31.0%

LYEL

-52.3%

Detailed metrics comparison

LYEL

Lyell Immunopharma Inc

RNAC

Cartesian Therapeutics Inc

Market Cap

LYEL$203M

RNAC$207M

Enterprise Value

LYEL$130M

RNAC$113M

Price

LYEL$8.71

RNAC$7.06

P/E Ratio

LYELN/A

RNACN/A

P/S Ratio

LYEL7,526.09x

RNAC140.34x

EV/Sales

LYEL4,822.94x

RNAC76.18x

EV/EBITDA

LYEL0.00x

RNAC0.00x

P/B Ratio

LYEL0.97x

RNAC296.12x

P/FCF Ratio

LYELN/A

RNACN/A

EV/FCF

LYEL-0.74x

RNAC-1.43x

PEG Ratio

LYELN/A

RNACN/A

Forward P/E (NTM)

LYELN/A

RNACN/A

Forward P/S (NTM)

LYEL16,911.71x

RNAC473.62x

Revenue (TTM)

LYEL$27K

RNAC$1M

Revenue Growth (YoY)

LYEL-55.0%

RNAC-20.7%

Forward Rev Growth

LYEL7184.7%

RNAC-14.0%

Gross Margin (TTM)

LYEL0.0%

RNAC0.0%

Operating Margin (TTM)

LYEL0.0%

RNAC0.0%

EBITDA Margin (TTM)

LYEL-669059.3%

RNAC-6503.1%

Net Margin (TTM)

LYEL-920285.2%

RNAC-10422.5%

FCF Margin (TTM)

LYEL-648763.0%

RNAC-5322.4%

Net Income (TTM)

LYEL$-248M

RNAC$-154M

FCF (TTM)

LYEL$-175M

RNAC$-79M

EPS (TTM)

LYEL-$10.64

RNAC-$5.16

ROE (TTM)

LYEL-9162.0%

RNAC-321582.0%

ROA (TTM)

LYEL-7050.0%

RNAC-4761.0%

ROIC (TTM)

LYEL-9162.0%

RNAC-321582.0%

Cash

LYEL$73M

RNAC$148M

Debt

LYEL$0

RNAC$53M

Net Cash/Debt

LYEL$73M

RNAC$95M

Current Ratio (TTM)

LYEL5.36x

RNAC7.48x

Quick Ratio (TTM)

LYEL5.12x

RNAC7.19x

Debt/Equity (TTM)

LYEL0.00x

RNAC0.28x

Debt/Assets (TTM)

LYEL0.0%

RNAC0.0%

Interest Coverage (TTM)

LYELN/A

RNACN/A

Net Debt/EBITDA (TTM)

LYEL0.00x

RNAC0.00x

Beta

LYEL-0.04

RNAC0.74

52W Performance

LYEL-52.3%

RNAC-31.0%

YTD Performance

LYEL-69.9%

RNAC4.4%

% from 52W High

LYEL-80.6%

RNAC-35.9%

% from 52W Low

LYEL6.1%

RNAC26.0%

Asset Turnover (TTM)

LYEL0.00x

RNAC0.01x

FCF Yield (TTM)

LYEL-86.2%

RNAC-37.9%

Earnings Yield (TTM)

LYEL-122.3%

RNAC-74.3%

Dividend Yield (TTM)

LYELN/A

RNACN/A

Rule of 40

LYEL-648,818.0

RNAC-5,343.1

EV/GP/RG

LYELN/A

RNACN/A

Ticker research

View LYEL research View RNAC research

Metric	LYEL Lyell Immunopharma Inc	RNAC Cartesian Therapeutics Inc
Market & Valuation
Market Cap	$203M	$207M
Enterprise Value	$130M	$113M
Price	$8.71	$7.06
P/E Ratio	N/A	N/A
P/S Ratio	7,526.09x	140.34x
EV/Sales	4,822.94x	76.18x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	296.12x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.74x	-1.43x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	16,911.71x	473.62x
Revenue & Growth
Revenue (TTM)	$27K	$1M
Revenue Growth (YoY)	-55.0%	-20.7%
Forward Rev Growth	7184.7%	-14.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-669059.3%	-6503.1%
Net Margin (TTM)	-920285.2%	-10422.5%
FCF Margin (TTM)	-648763.0%	-5322.4%
Net Income (TTM)	$-248M	$-154M
FCF (TTM)	$-175M	$-79M
EPS (TTM)	-$10.64	-$5.16
ROE (TTM)	-9162.0%	-321582.0%
ROA (TTM)	-7050.0%	-4761.0%
ROIC (TTM)	-9162.0%	-321582.0%
Financial Health
Cash	$73M	$148M
Debt	$0	$53M
Net Cash/Debt	$73M	$95M
Current Ratio (TTM)	5.36x	7.48x
Quick Ratio (TTM)	5.12x	7.19x
Debt/Equity (TTM)	0.00x	0.28x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.04	0.74
52W Performance	-52.3%	-31.0%
YTD Performance	-69.9%	4.4%
% from 52W High	-80.6%	-35.9%
% from 52W Low	6.1%	26.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-86.2%	-37.9%
Earnings Yield (TTM)	-122.3%	-74.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-648,818.0	-5,343.1
EV/GP/RG	N/A	N/A
Ticker research	View LYEL research	View RNAC research